October 19, 2024
Sustained Drug Delivery Articles
July 23, 2024
Two-year Data on Susvimo Reported at ASRS
July 18, 2024
Interim Phase 1 HELIOS Trial Data of Axpaxli for NPDR Presented at ASRS
By Jennifer Ford, senior managing editor
July 1, 2024
ANI Pharmaceuticals to Acquire Alimera Sciences
June 24, 2024
Macular Telangiectasia: New Hope on the Horizon
By Thomas A. Albini, MD, Michael A. Singer, MD
April 1, 2024
Upfront: Innovations in VEGF Inhibition Delivery
By Peter K. Kaiser, MD
April 1, 2024
Clinical Trial Update April 2024
April 1, 2024
Improving Durability of Drugs in Wet AMD
By Lucas W. Rowe, MD, Thomas A. Ciulla, MD, MBA
April 1, 2024
Polymeric Technologies for Retinal Drug Delivery
By Xinyi Su, PhD, MMed, FAMS, MBChir, Ivan Seah, MBBS, MBA, MPH
April 1, 2024
Subspecialty News April 2024
By Rochelle Nataloni, contributing writer
April 1, 2024
Tyrosine Kinase Inhibitors for Wet AMD and Diabetic Retinopathy
By Nikhil Das, MD, Katherine E. Talcott, MD
April 1, 2024
Broader VEGF Pathway Inhibition for Wet AMD
By Mark R. Barakat, MD, Mark P. Breazzano, MD
March 1, 2024
Subspecialty News March 2024
By Rochelle Nataloni, contributing writer
January 1, 2024
Subspecialty News January/February 2024
By Rochelle Nataloni, contributing writer
January 1, 2024
EyePoint Reports Positive Results of Phase 2 Trial for Investigational AMD Treatment
By Jim Gallagher, senior managing editor
October 1, 2023
CLINICAL TRIAL DOWNLOAD: Twelve-month Data From a Phase 1 Clinical Trial of OTX-TKI for Wet AMD
By Arshad M. Khanani, MD, MA, FASRS, Paula Pecen, MD, Rabia Gurses Ozden, MD
September 1, 2023
Glycoimmune Therapy as a Novel Treatment Approach for Geographic Atrophy
By Sophie J. Bakri, MD, MBA, Jeffrey S. Heier, MD, Arshad M. Khanani, MD, MA, FASRS, et al.
September 1, 2023
Clinical Trial Update September 2023
July 1, 2023
Clinical Trial Update July/August 2023
June 1, 2023
Steroid Options for Treatment of Uveitis
By Russel Dinh, Brian K. Do, MD
May 1, 2023
Polymers for Retinal Drug Delivery
By Charles D. Blizzard, Dina Akasheh, PhD, Matthew Cheung, PharmD, et al.
May 1, 2023
Clinical Trial Update May 2023
April 1, 2023
Clinical Trial Update April 2023
March 1, 2023
Clinical Trial Update March 2023
February 1, 2023
Clinical Trial Update: Special Edition 2023
January 1, 2023
SUBSPECIALTY NEWS: Progress toward GA drug approval, new gene therapy data, and more.
By Rochelle Nataloni, contributing writer
January 1, 2023
Clinical Trial Update January/February 2023
October 1, 2022
Sustained-release Tyrosine Kinase Inhibitors for the Treatment of nAMD
By Arshad M. Khanani, MD, MA, FASRS, Carl D. Regillo, MD, FACS, Charles C. Wykoff, MD, PhD, et al.
October 1, 2022
UPFRONT: Targeting Tyrosine Kinases in Retinal Disease
By Peter K. Kaiser, MD
August 1, 2022
Suprachoroidal Drug Delivery Technology
By Thomas A. Ciulla, MD, MBA, Rafael V. Andino, MSBE, MBA, Shelley Hancock, MBA
August 1, 2022
Flow Mechanics of Suprachoroidal Injection
By VENKATKRISH M. KASETTY, MD, Luke G. Qin, Diego Espinosa-Heidmann, MD, et al.
August 1, 2022
Suprachoroidal Delivery as a Novel Avenue for Retinal Gene Therapy
By Arshad M. Khanani, MD, MA, FASRS, Hannah Khan, MPH, Tyler M. Ewing, MS
August 1, 2022
Light-activated Suprachoroidal Therapy for the First-line Treatment of Indeterminate Lesions and Small Choroidal Melanoma
By Buse Guneri Beser, MD, FEBO, FICO, Hakan Demirci, MD
August 1, 2022
New Developments in Suprachoroidal and Subretinal Drug Delivery Technology
By David Xu, MD, M. Ali Khan, MD, Allen C. Ho, MD
August 1, 2022
Suprachoroidal Drug Delivery in the Treatment of Noninfectious Uveitis
By Steven Yeh, MD, Tolulope Fashina, MD, MPH
August 1, 2022
SPONSOR WELCOME LETTER: What Is the Real Potential of the Suprachoroidal Space?
By Joseph Ponzo
August 1, 2022
GUEST EDITORIAL: An Inflection Point for Retinal Therapy
By Mark R. Barakat, MD
August 1, 2022
UPFRONT: A Journey to the Suprachoroidal Space
By Peter K. Kaiser, MD
January 1, 2022
SUBSPECIALTY NEWS: Real-world Iluvien data, advances to program for choroidal melanoma treatment, results for at-home OCT, and more.
By Rochelle Nataloni, contributing writer
Advertisement
Recommendations
Advertisement